At the 44th Annual J.P. Morgan Healthcare Conference, Revvity’s CEO Prahlad Singh provided an overview of the company’s strategic progress since its spin-out, highlighting quarterly guidance figures as of the October 27, 2025 earnings call. Singh noted that Revvity has completed a multi-year portfolio transformation, transitioning from a predominantly industrial business into three core segments: analytical solutions, small-molecule preclinical life sciences, and diagnostics. Each segment now represents approximately one-third of overall revenues. He reiterated management’s full-year outlook for mid-teens percentage revenue growth and an adjusted EBITDA margin expansion of 200 basis points, based on estimates from the 2025 third-quarter earnings guidance. Singh also emphasized ongoing investments in next-generation assay technologies and bioprocessing platforms, forecasting that R&D expenditures will increase by 10% year-over-year to support new product launches in early 2026.